Brief: Melt Pharmaceuticals Says Co Expects To Begin MELT-300 Phase 3 Program in Q1 2024

Harrow

03/01/2024 12:25

Jan 3 (Reuters) - Harrow Inc  HROW.O :
    * MELT PHARMACEUTICALS PROVIDES CORPORATE UPDATE
    * MELT PHARMACEUTICALS INC - PAID IN FULL ALL OUTSTANDING
PRINCIPAL AND ACCRUED AND UNPAID INTEREST UNDER ITS LOAN
FACILITY WITH HARROW
    * MELT PHARMACEUTICALS INC -  RECENTLY RECEIVED A WRITTEN
RESPONSE
FROM U.S. FDA REGARDING ITS PLANNED MELT-300 PHASE 3 PROGRAM
    * MELT PHARMACEUTICALS INC:  BASED ON FDA'S RESPONSE, MELT
PHARMACEUTICALS EXPECTS TO BEGIN PHASE 3 PROGRAM ACTIVITIES IN
Q1 OF 2024

Source text for Eikon:  ID:nBw2lWCxLa 
Further company coverage:  HROW.O 

 ((Reuters.Briefs@thomsonreuters.com;))